From beta to alpha: understanding the next generation of radiopharmaceutical therapies
Radiopharmaceutical innovation is accelerating, with multiple promising agents approved or in development that have the potential to reshape the cancer treatment landscape. This article provides a clear, clinician-focused overview of where the field currently stands and where it is heading, for an audience increasingly likely to encounter these therapies in their practice. The article outlines […]
Dr Juliana Maynard
Medicines Discovery Catapult
